Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Portfolio Pulse from Vandana Singh
Roche missed out on acquiring a potential blockbuster weight-loss drug, orforglipron, which Eli Lilly acquired for $50 million and is projected to generate up to $14 billion annually by 2032. Roche's cautious approach, influenced by past setbacks, led to this missed opportunity. Roche re-entered the obesity market in 2023 but is expected to lag behind competitors like Eli Lilly and Novo Nordisk.
August 16, 2024 | 5:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novo Nordisk faces competition from Eli Lilly's orforglipron, which is easier to manufacture and distribute than Novo Nordisk's oral semaglutide.
Eli Lilly's orforglipron is expected to dominate the market due to its ease of manufacturing and distribution, posing a competitive threat to Novo Nordisk's oral semaglutide.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 50
NEGATIVE IMPACT
Roche missed out on acquiring orforglipron, a potential blockbuster weight-loss drug, and is now playing catch-up in the market. Roche's new weight-loss pill is not expected to launch before 2028.
Roche's decision to pass on orforglipron and its late re-entry into the weight-loss market will likely result in a competitive disadvantage, with its new product not expected before 2028.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Eli Lilly acquired the weight-loss drug orforglipron, which is projected to generate up to $14 billion annually by 2032. This acquisition positions Eli Lilly as a leader in the weight-loss market.
Eli Lilly's acquisition of orforglipron, a drug with massive revenue potential, positions the company as a leader in the weight-loss market. The projected $14 billion annual revenue by 2032 is a significant positive impact.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100